कंपनी का अवलोकन
DarioHealth Corp. functions as a digital health entity that provides personalized and dynamic interventions through its digital therapeutics platform and suite of solutions for conditions including diabetes, hypertension, and weight management. This organization operates within the broader Healthcare sector, specifically focusing on the Health Information Services industry, where it leverages data analytics and one-on-one coaching to deliver its services both domestically and internationally. The company currently maintains a market capitalization of $51.83M, generates annual revenue of $22.36M, and employs a workforce of 160 individuals. These valuation and revenue figures indicate that DarioHealth Corp. operates as a mid-cap entity with a revenue base that supports its operational scale but reflects the early-stage characteristics often found in the health information services market. The combination of a relatively modest market cap and a specific employee count suggests a company that is scaling its digital infrastructure to capture value in a specialized niche of the healthcare economy.
वित्तीय स्वास्थ्य
The financial performance of the company is characterized by a trailing twelve-month revenue of $22.36M, which contrasts sharply with a net income of $-40,309,576 and an EBITDA of $-33,517,000. This significant gap between total revenue and net income reveals a cost structure where expenses, likely driven by high operational costs or heavy investment in technology development, substantially erode profitability before taxes and interest are considered. Furthermore, the company reports a free cash flow of $-11,204,875, which indicates that cash outflows for capital expenditures and working capital exceed cash generated from operations, thereby limiting immediate financial flexibility for unplanned strategic acquisitions. When analyzing profitability efficiency, the gross margin stands at 64.1%, suggesting effective cost control relative to the cost of goods sold in its digital service delivery model. However, the operating margin is negative at -163.7%, and the profit margin is even more negative at -186.6%, indicating that operating expenses far exceed gross profit and that the bottom line is heavily impacted by non-operating items or significant structural costs. Regarding liquidity and solvency, the company holds $26.02M in cash against $31.75M in debt, resulting in a debt-to-equity ratio of 46.74, which classifies the balance sheet as highly leveraged given the negative equity position implied by the financial ratios. Despite this leverage, the current ratio of 3.76 suggests that the company possesses sufficient current assets to cover its short-term liabilities multiple times over, providing a buffer against immediate liquidity crises. Finally, the return on equity is -59.6% and the return on assets is -20.0%, metrics that reveal that management is currently destroying value rather than generating returns for shareholders or utilizing assets efficiently.
मूल्यांकन आकलन
Valuation metrics for DarioHealth Corp. present a complex picture due to the company's lack of positive earnings, resulting in a trailing P/E ratio that is listed as N/A and a forward P/E of -16.32. The negative forward P/E implies that the market is pricing the stock based on expectations of future earnings turnaround rather than current profitability, though the negative sign itself denotes that projected earnings are still negative in the forward model. The price-to-book ratio is 0.72, which indicates that the market values the company at a discount to its book value, suggesting a lack of market premium or that the intangible assets on the balance sheet are not fully reflected in the market price. Alternative valuation measures include a price-to-sales ratio of 2.32 and an EV/EBITDA of -1.72, which suggest that investors are willing to pay over two times the sales figure despite the lack of earnings, relying instead on revenue growth potential in the digital health sector. The stock has exhibited significant volatility, trading within a 52-week range bounded by a high of $17.74 and a low of $5.93, meaning the current trading price sits at a point where the market sentiment fluctuates between these extremes without indicating a definitive trend direction. The beta value of 1.28 indicates that the stock price is more volatile than the broader market, moving approximately 28% more than the market index during periods of fluctuation. This high sensitivity to market movements is typical for small-cap technology and healthcare stocks that are heavily influenced by sector-specific regulatory and adoption trends.
Growth & Income
The company's growth trajectory is currently constrained by a revenue growth rate of -31.2% year-over-year, while earnings growth is N/A due to the absence of positive net income. The fact that revenue is shrinking while earnings remain negative implies that the decline in sales is exacerbating the company's losses rather than stabilizing its bottom line. As a non-dividend payer, DarioHealth Corp. maintains a dividend yield of N/A and a payout ratio of 0.0%, reflecting the standard practice for growth-oriented or distressed firms that reinvest limited capital back into operations rather than distributing income to shareholders. This lack of dividend distribution is consistent with the company's negative free cash flow and negative retained earnings, necessitating a focus on operational efficiency and cost reduction rather than shareholder returns. The overall growth and income profile indicates a company in a contractionary phase regarding sales that has yet to demonstrate a path to profitability, relying entirely on the potential for future market expansion in the digital therapeutics space to reverse its current financial trajectory.